SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

A quarterly earnings beat, raised outlook and record AI-compute backlogalongside managements emphasis on customer prepayments and contract-backed financingsparked an after-hours rebound and widespread short-squeeze chatter. Bulls see strong demand and improved financing prospects, while skeptics remain concerned about heavy debt, interest costs, capital spending and the path to sustained cash flow.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff is centered on governance and national-security concerns surrounding CEO Jensen Huangs relationship with a customer suspected of ties to Chinese intelligence, with traders debating whether the investigation and China chip-export questions could threaten his leadership or the business. Others see the drop as an overreaction and are buying the dip, while looking to the upcoming earnings report for a business-focused counterpoint.

Autonomi (ANT) is a cryptocurrency launched in 2025and operates on the Arbitrum platform. Autonomi has a current supply of 1,200,000,000 with 346,011,579 in circulation. The last known price of Autonomi is 0.03102024 USD and is up 12.83 over the last 24 hours. It is currently trading on 15 active market(s) with $148,822.58 traded over the last 24 hours. More information can be found at https://autonomi.com.

Aragon

Attention is heavily muddied by Anthropic IPO chatter mistakenly tagged to Aragons ANT token. The Aragon-specific discussion centers on the projects dissolution and completed token-redemption initiative, with holders unsure about conversion or exchange availability; other posts are mostly speculative trading reactions.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and conference call are driving attention, with traders debating the shift to recurring Samsung and Micron licensing revenue and the stronger balance sheet against an apparent estimates miss caused partly by amortizing Samsungs upfront fee over the agreement term. Bullish traders point to higher expected Q4 revenue, while skeptics cite lower product sales and the lack of a confirmed SK Hynix deal or Nasdaq uplisting.

NextNav, Inc. engages in development of positioning, navigation, and timing solutions. Its products include NextNav Pinnacle, NextNav 3D, and NextNav TerraPoiNT. The company was founded by Ganesh Pattabiraman and Arun Raghupathy in May 2021 and is headquartered in Reston, VA.

NextNav Inc

NextNavs Q3 earnings report and conference call are driving immediate discussion, with traders noting an EPS beat but reacting to the share-price decline and debating whether the call offered meaningful progress. Many see the pending FCC rulemaking on the companys spectrum as the more important catalyst, while the bullish SpaceX-related thesis remains speculative and others point to regulatory delays and downside risk.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

INFQ is drawing attention ahead of its quarterly report, with traders looking for revenue, guidance and commercialization updates that could set it apart from other quantum companies. Optimism about its products and technical progress is countered by concerns over weak price action and volatility alongside the broader quantum and tech sectors.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zetas strong quarterly earnings beat and raised guidance have driven attention, with traders citing accelerating growth, improving profitability and analyst upgrades as support for the rally. The reaction is split between bulls expecting momentum to continue and skeptics focused on volatile post-earnings trading and resistance near recent levels.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos weaker-than-expected quarterly update and narrowed production outlook, amid Cigar Lake operating setbacks, are driving a sharp selloff and bearish discussion about further downside. Some traders see the decline as an opportunity, arguing that firm uranium-market fundamentals and longer-term nuclear demand remain intact.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs quarterly resultsstrong revenue and backlog growth but a wider-than-expected loss and Neutrons first launch pushed to 2027are driving the discussion. Traders are split between viewing the demand and backlog as evidence of growth and worrying about execution delays, ongoing losses, and dilution; shares have rebounded after the initial post-earnings selloff.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Anthropics new Claude workplace tools, including a spreadsheet product positioned against Excel, have raised concerns that Microsofts Office and Copilot franchises face stronger competition. Traders debate whether the threat is material or overstated given Microsofts entrenched enterprise ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -100.00% and -84.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) to Release Earnings on Monday

Sangamo Therapeutics (NASDAQ:SGMO) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totaling 42,883,635 shares, an increase of 14.0% from the March 31st total of 37,605,702 shares. Based on an average daily...

Sangamo Therapeutics (NASDAQ:SGMO) Insider Sells $17,456.75 in Stock

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) insider Gregory Davis sold 69,827 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of...

Sangamo Therapeutics (NASDAQ:SGMO) SVP Sells $89,944.92 in Stock

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) SVP Nathalie Dubois-Stringfellow sold 345,942 shares of Sangamo Therapeutics stock in a transaction on Tuesday, April 21st. The stock was...

Gregory Davis Sells 69,827 Shares of Sangamo Therapeutics (NASDAQ:SGMO) Stock

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) insider Gregory Davis sold 69,827 shares of the firm's stock in a transaction dated Wednesday, April 22nd. The shares were sold at an...

Sangamo Therapeutics (NASDAQ:SGMO) Lowered to Strong Sell Rating by Zacks Research

Zacks Research lowered shares of Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Thursday...

HC Wainwright Has Negative Forecast for SGMO FY2026 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Stock analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Sangamo Therapeutics in a research note issued...

Equities Analysts Issue Forecasts for SGMO FY2028 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright reduced their FY2028 earnings per share estimates for shares of Sangamo Therapeutics in a report released on Thursday, April...

Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today

Equity

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.

Sangamo Therapeutics expects GAAP total operating expenses to be approximately $110M to $130M in 2026, with non-GAAP expenses ranging from $100M to $120M, subject to securing adequate additional funding.

Sangamo Therapeutics' revenues decreased significantly, and its cash runway is limited to Q3 2026, compounded by a Nasdaq delisting to OTCQB Venture Market.

Sangamo Therapeutics is advancing its ST-920 BLA submission for Fabry disease with clear FDA pathways and progressing its neurology pipeline, including ST-503 and ST-506 programs.

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Sangamo Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>PEPG fell after its Phase 2 Freedom 2 study showed no meaningful improvements in walking speed or hand strength at the starting dose of 5 mg/kg.</li><li>SGMO slipped after reporting a Q4 loss per share of $0.11 versus the expected loss of $0.05, even as revenue rose to $14.23 million from $7.55 million a year earlier.</li><li>PHR declined after cutting its FY27 revenue outlook to $510 million-$520 million from $545 million-$559 million, below analyst expectations of $552.1 million.</li></ul>Shares of PepGen (PEPG), Sangamo Therapeutics (SGMO), and Phreesia (PHR) were among the top premarket losers on Tuesday as investors reacted to muted functional trial results, a wider-than-expected loss, and a revenue outlook cut, prompting analyst downgrades.In early premarket trading on Tuesday, PEPG plunged 45%, SGMO fell 19%, and PHR slumped 27%.<h2 class="st-heading-2">PepGen Trial Shows No Functional Gains At Low Dose</h2>PepGen reported results from the lowest-dose cohort in its Phase 2 Freedom 2 study of PGN-EDODM1 in patients with myotonic dystrophy type 1, with investors focusing on the lack of functional improvement at the starting dose.The company said the therapy was generally well tolerated, with all adverse events mild or moderate and no serious adverse events reported. However, the company also said patients showed “no meaningful improvements” in walking speed or hand strength at the starting 5 mg/kg dose of PGN-EDODM1.PepGen said patients receiving the treatment showed an average 7.3% improvement on a disease-related molecular metric, compared with 6.8% in placebo patients, rising to 22.9% after excluding one outlier. The company expects results from the higher 10 mg/kg cohort in the second half of 2026, with cash expected to support operations into the second half of 2027.<h2 class="st-heading-2">Sangamo Loss Widens As Funding Outlook Weighs</h2>Sangamo Therapeutics reported a fourth-quarter (Q4) loss per share of $0.11, wider than analyst expectations for a loss of $0.05, even as revenue rose to $14.23 million from $7.55 million a year earlier.The company highlighted progress in its Fabry disease gene therapy program, saying it is “well advanced in the rolling submission of the BLA to the FDA under the Accelerated Approval pathway” following positive topline results from the registrational STAAR study.However, sentiment appeared pressured after the company said its 2026 expense outlook is “subject to our ability to secure adequate additional funding for our current operating plan.” Sangamo expects non-GAAP operating expenses of $110 million to $120 million in 2026.<h2 class="st-heading-2">Phreesia Guidance Cut Triggers Broker Downgrades</h2>Phreesia reported Q4 revenue of $127.1 million, slightly above analyst expectations of $126.6 million, while adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose to $29.4 million from $16.4 million a year earlier.Shares fell after the company lowered its fiscal 2027 revenue outlook to $510 million to $520 million, down from $545 million to $559 million, and below analyst expectations of $552.1 million. The company said, “Network solutions clients are committing lower spend levels for the second half of fiscal 2027 than we had anticipated last December.”Following the guidance cut, Baird downgraded the stock to ‘Neutral’ from ‘Outperform’ and reduced its price target to $10 from $25, saying “the magnitude of the follow-on impact exceeded expectations.” Truist Securities also downgraded the stock to ‘Hold’ from ‘Buy’ and lowered its price target to $11 from $24, citing “the meaningful reduction to the revenue outlook.”<h2 class="st-heading-2">How Do Retail Traders Feel About PEPG, SGMO And PHR?</h2>On Stocktwits, retail sentiment for PEPG, SGMO and PHR was ‘extremely bullish’ amid ‘extremely high’ message volume.Over the past year, PEPG has risen 186%, while SGMO has fallen 63% and PHR has declined 56%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/unh-stock-below-buffett-entry-price-first-revenue-decline-30-years-ai/cZEPohoRINz">UNH Stock Slides Back Below Warren Buffett’s Entry Price As Annual Revenue Faces First Decline In 30 Years — AI May Be Long-Term Fix</a>

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.  In early premarket trading on Tuesday, PEPG plunged 45%, SGMO fell 19%, and PHR slumped 27%

PepGen Inc

Phreesia Inc

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Current Price	$0.11
Prev Close	$0.11
Open	$0.10
Dividend Yield	0.00%
50-Day Moving Average	$0.1357
Beta	1.86
Avg. Volume	1.52M
PE Ratio	-0.29

52-Week High	$0.60
52-Week Low	$0.01
Market Capitalization	$45.57M
EPS (Annual)	-$0.4387
Price to Book	-2.40
Revenue Per Employee	$278,535.21

Feed

News

Sentiment

Earnings

Fundamentals

Info

SGMO Fundamentals